- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Daxor received FDA clearance for its diagnostic and presented findings in New York City.
4 reports, 1 independent
Updated Sep 1
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Daxor received FDA clearance for its diagnostic and presented findings in New York City.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireDaxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in bl
- GlobeNewswireDaxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the g
- GlobeNewswireDaxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor B